Aerovate Therapeutics (NASDAQ:AVTE) & AEON Biopharma (NASDAQ:AEON) Financial Contrast
by Doug Wharley · The Cerbat GemAEON Biopharma (NASDAQ:AEON – Get Free Report) and Aerovate Therapeutics (NASDAQ:AVTE – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, profitability and risk.
Profitability
This table compares AEON Biopharma and Aerovate Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| AEON Biopharma | N/A | N/A | -994.63% |
| Aerovate Therapeutics | N/A | -90.19% | -77.47% |
Analyst Recommendations
This is a summary of recent ratings for AEON Biopharma and Aerovate Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| AEON Biopharma | 0 | 1 | 1 | 1 | 3.00 |
| Aerovate Therapeutics | 0 | 0 | 0 | 0 | 0.00 |
Risk & Volatility
AEON Biopharma has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500. Comparatively, Aerovate Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500.
Institutional & Insider Ownership
22.8% of AEON Biopharma shares are held by institutional investors. 0.9% of AEON Biopharma shares are held by company insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares AEON Biopharma and Aerovate Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| AEON Biopharma | N/A | N/A | -$36.63 million | ($2.43) | -0.41 |
| Aerovate Therapeutics | N/A | N/A | -$75.52 million | ($1.70) | -11.33 |
Aerovate Therapeutics is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.
Summary
AEON Biopharma beats Aerovate Therapeutics on 7 of the 11 factors compared between the two stocks.
About AEON Biopharma
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.
About Aerovate Therapeutics
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.